NCT01219777View on ClinicalTrials.gov

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2015

Conditions
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Interventions
DRUG

carboplatin

Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.

DRUG

Bevacizumab

Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.

DRUG

Paclitaxel

60-80 mg/m2 administered on Day 1, 8 \& 15 during cycle 1-3. Treatment cycle consists of 21 days duration.

Trial Locations (1)

43210

The Ohio State University Medical Center, Columbus

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Ritu Salani

OTHER